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The NF-E2-related factor 2 (Nrf2) is a key transcrip-
tional regulator of antioxidant defense and detoxifi-
cation. To directly monitor stabilization of Nrf2, we
fused itsNeh2domain, responsible for the interaction
with its nucleocytoplasmic regulator, Keap1, to firefly
luciferase (Neh2-luciferase). We show that Neh2
domain is sufficient for recognition, ubiquitination,
and proteasomal degradation of Neh2-luciferase
fusion protein. The Neh2-luc reporter system allows
direct monitoring of the adaptive response to redox
stress and classification of drugs based on the
time course of reporter activation. The reporter was
used to screen the Spectrum library of 2000 biologi-
cally active compounds to identify activators of
Nrf2. The most robust and yet nontoxic Nrf2 activa-
tors found—nordihydroguaiaretic acid, fisetin, and
gedunin—induced astrocyte-dependent neuropro-
tection from oxidative stress via an Nrf2-dependent
mechanism.
INTRODUCTION
Oxidative stress is amajor contributor to aging, insulin resistance,
andneurodegeneration. Anemergent strategy for restoring redox
homeostasis involves activation of the transcription factor, Nrf2
(nuclear factor erythroid 2-related factor 2), a member of the
cap’n’collar family of basic leucine zipper transcription factors
that regulates a coordinated adaptive gene program (Moi et al.,
1994). Indeed, activators of the Nrf2 response are beneficial for
the treatment and prevention of chronic degenerative diseases,
whereas inhibitors of Nrf2 may help to fight cancer (Calabrese
et al., 2008; Hayes andMcMahon, 2009; Lau et al., 2008). Amajor
challenge in the development of effective Nrf2 activators is to
identify those that lead specifically to Nrf2 stabilization and
consequent promoter activationwithout imposing general oxida-
tive/electrophilic stress.752 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 ElsevierNrf2 is sequestered under homeostatic conditions by binding
to its inhibitory protein, Keap1 (Kelch-like ECH-associated
protein-1) (Motohashi and Yamamoto, 2004; Itoh et al., 1999).
Keap1 serves as a bridge between Nrf2 and the Cul3-Rbx1
E3 ubiquitin ligase, leading to Nrf2 ubiquitination and thereby
targeting Nrf2 for degradation by the 26S proteasome (Kobaya-
shi et al., 2004; Cullinan et al., 2004; Zhang et al., 2004). Upon
exposure to oxidative stress, xenobiotics, or electrophilic
compounds, the Nrf2 protein is released from its complex with
Keap1 and translocates to the nucleus. There, it forms hetero-
dimers with other transcription regulators, such as small Maf
proteins, and induces the expression of antioxidant genes
controlled by the antioxidant response element (ARE) (Kaspar
et al., 2009).
Nrf2 is composed of Neh1–Neh6 domains, amongwhich Neh2
is the putative negative regulatory domain that interacts with
Keap1, Neh4 and Neh5 are transactivation domains, and Neh1
is the binding domain for ARE (Tong et al., 2006b). The functional
domains of Keap1 are the Broad complex, Tramtrack andBric-a-
Brac (BTB), the intervening region (IVR), the double glycine
repeats domain (DGR), and the C-terminal region (CTR) (Tong
et al., 2006b). Two motifs in the Neh2 domain, i.e., ETGE and
DLG, are recognized by the Keap1 homodimer in a hinge-latch
mode (Tong et al., 2006a, 2006b, 2007). Keap1 mediates poly-
ubiquitination of the positioned lysines within the central a helix
of the Neh2 domain under homeostatic conditions. Under oxida-
tive/electrophilic stress, reactive cysteines within Keap1 are
modified, and thus, Keap1 undergoes conformational changes
that lead to the detachment of the weak-binding DLG, resulting
in Nrf2 stabilization. However, debate remains as to whether
Nrf2 is completely released from its complex with Keap1 (Zhang,
2006) or not. Nrf2 activators identified so far are represented by
potent alkylating agents (Dinkova-Kostova et al., 2004) and
redox active compounds like diphenols, aminophenols, and
phenylene diamines, the precise mechanism of action of which
is controversial. Recent data show an enhanced effect of these
compounds in the presence of exogenously added copper
(Wang et al., 2010).
Current techniques for monitoring Nrf2 activation include
the ARE-luciferase (Moehlenkamp and Johnson, 1999), Nrf2Ltd All rights reserved
Figure 1. Development of Neh2-luc
Reporter
(A) Schematic presentation of reporter func-
tioning.
(B) Time course of the Neh2-luc reporter response
to TBHQ compared to that for the commonly used
ARE-luc reporter.
(C) Time course of Neh2-luc and HIF ODD-luc
reporter responses to lactacystin showing the
lag period shortening with rising concentrations
of the proteasomal inhibitor and, thus, confirming
the switch of the rate-limiting step from specific
recognition to proteasomal degradation. All
values are presented as mean ± SEM. Increased
expression of Nrf2-regulated genes in the Neh2-
luc reporter line as a result of rescue of endoge-
nous Nrf2 in the presence of the overexpressed
Neh2-luciferase fusion, and the reporter response
to canonical Nrf2 activators—PGJ2, TBHQ, and
sulforaphane—in comparison to the absence of
any response for HIF ODD-luc reporter (to confirm
the specificity of each reporter) are shown in
Figure S1.
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human placental alkaline phosphatase reporter systems (Son
et al., 2010). Recently, a GFP fusion protein with the Nrf2 ZIP
domain was utilized to study Nrf2 nuclear translocation (Theodore
et al., 2008), whereas GFP fusion with the C. elegans Nrf2 analog
was used to analyze Nrf2 activation by proteasomal dysfunction
(Kahn et al., 2008). The ARE-GFP reporter assay was used to
screen the libraryof 2000biologically activecompounds (Spectrum
library), and 45 hitswere identified (Shaw et al., 2010), with androg-
rapholidebeing themostpotent. TheuseofARE-luciferase reporter
for high throughput screening (HTS) purposes has been recently
published (Hur et al., 2010). The screen of 1.5 million compounds
resulted in discovery of novel alkylating agents targeting Cys 151
in Keap1 as well as a dozen other cellular proteins, including phos-
phatase 2a, and HDAC1 and HDAC2 (Hur et al., 2010). Here, weChemistry & Biology 18, 752–765, June 24, 2011present a new reporter construct, the
Neh2 domain fused to a luciferase gene
(Neh2-luc), as a powerful tool for the HTS
and real-timemonitoring ofNrf2 activation.
We also demonstrate the utility of the
Neh2-luc model to identify and classify
compounds capable of inducing Nrf2-
specific astrocyte-dependent neuropro-




The PCMV-driven Neh2-luc reporter
supports the constitutive, intracellular
synthesis of a fusion protein composed
of the human Neh2 domain (1–97 aa)
and firefly luciferase. Because the Neh2
domain is known to be sufficient for
recognition by the ubiquitin-ligase com-plex and subsequent ubiquitination of the fusion protein, the
recombinant luciferase-labeled protein should undergo protea-
somal degradation. The steady-state concentration of the fusion
protein should correspond to the equilibrium between its
synthesis and degradation (Figure 1A). The background lumines-
cence signal calibrated with recombinant luciferase allows us
to estimate the steady-state concentration of the Neh2-lucif-
erase fusion protein: the background is15–20 rlu, which corre-
sponds to 0.25–0.33 pg luciferase protein and is more than two
orders of magnitude lower than that observed for the cell line
expressing wild-type (WT) luciferase under control of the same
promoter. The low steady-state luciferase activity (recalculated
as 0.6–0.8 nM fusion protein for 30,000 cell/well density and
233 m3 single-cell volume) suggests that despite forced expres-
sion of the Neh2-luciferase fusion protein, it is successfullyª2011 Elsevier Ltd All rights reserved 753
Figure 2. Neh2-Luc Reporter Response to Upregulation and Downregulation of Keap1 Levels
(A) Keap1 overexpression results in a decreased luminescence in Neh2-luc cells transduced by Keap1 adenovirus. The efficiency of transfection of Neh2-luc cell
line with FLAG-labeled Keap1-overexpressing adenovirus was 45%–70% as judged by immunostaining with anti-FLAG antibodies (seeFigure S2A).
(B) siRNA Keap1 knockdown results in an increased level of luminescence only in Neh2-luc cell line, but not in WT-luc line.
(C) siRNA Keap1 knockdown has no effect on luminescent signal in WT-luc line. All values are presented as mean ± SEM. The siRNA Keap1 knockdown was
confirmed by RT-PCR: it decreased levels of Keap1 mRNA and increased levels of mRNA of Nrf2-regulated genes in both Neh2-luc and WT-luc cell lines (see
Figure S2B).
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fully degraded. The findings support prior observations that the
Neh2 domain is critical for Keap1 binding and sufficient for
recognition and degradation of Neh2-containing fusion protein
(Zhang et al., 2004).
The overexpressed Neh2-luciferase fusion protein success-
fully competes with endogenous Nrf2 for Keap1 binding and,
thus, rescues endogenous Nrf2 from degradation: the reporter
cell line shows a 4- to 6-fold increase in mRNA for Nrf2-regulated
genes such asHO-1 andGSLM (see Figure S1A available online).
The reporter exemplifies the action of an ‘‘ideal Nrf2 activator’’
that stabilizes endogenousNrf2 by competing for Keap1 binding,
and not by modifying Keap1 chemically. Of note, stabilization of
endogenous Nrf2 and the upregulated expression of protective
genes may explain the increased stability of the reporter cell
line as compared to the original nontransfected cell line.
Canonical activators of Nrf2 such as 15-deoxy-prostaglandin
J2 (15d-PGJ2) (Itoh et al., 2004), sulforaphane (Myzak and Dash-
wood, 2006), and tert-butylhydroquinone (TBHQ) (Moehlenkamp
and Johnson, 1999) disrupt the interaction in the Neh2luc-
Keap1-Cul3 complex, leading to a measurable increase in lucif-
erase activity (Figure S1B). This effect is not observed for the
reporter cell line bearing another construct, HIF ODD-luciferase,
where HIF-1a oxygen degradable domain is fused to luciferase
(Smirnova et al., 2010), thus indicating the specific character of
Neh2-luc reporter response (Figure S1B).
If compared to commonly used ARE-luc reporter, the newly
developed one has an obvious advantage to monitor immediate
changes upon the addition of Nrf2 activators: the response of
ARE-luc reporter to TBHQ is 3 hr delayed (Figure 1B).
The response of both Neh2-luc and HIF ODD-luc reporters to
a proteasomal inhibitor is similar (Figure 1C): there is a concentra-
tion-dependent delay (lag period) in reporter response. The
shortening lag periods observed with rising concentrations of
the proteasomal inhibitor provide evidence for the switch of the
rate-limiting step from the disruption of the Neh2-Keap1-Cul3
complex to the proteasomal degradation step. The comparison
of Neh2-luc and HIF ODD-luc reporter performance with respect
to Nrf2 activators (Figure S1B) and proteasomal inhibitors (Fig-
ure 1C) proves the specific character of each reporter.754 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 ElsevierThe Neh2-luc reporter system is a novel tool to monitor the
direct effect of a particular compound on the first step controlling
Nrf2stability, i.e.,Nrf2-Keap1and/orKeap1-Cul3 interaction.Vali-
dation studies further performed using traditional approaches
(Figure 2) demonstrate that Keap1 regulates the stability of
the Neh2 reporter in the same manner as for endogenous Nrf2:
forced expression of Keap1 in the Neh2-luc reporter cell line (Fig-
ure S2A) led to a 3.5-fold decrease in the background lumines-
cence (Figure 2A). In contrast, Keap1 reduction by siRNA resulted
in a steady-state increase in Neh2-luc reporter activity (Figure 2B)
and an induction of transcription of Nrf2-regulated genes in both
Neh2-luc and WT-luc-expressing cell lines (Figure S2B). Keap1
depletion had no effect on the levels or activity of a native firefly
luciferase expressed under the same CMV promoter, confirming
the key role of the Neh2 domain in the Keap1-dependent regula-
tion of the Neh2-luciferase fusion protein (Figure 2C). The results
ofKeap1overexpression (Figure2A)orsiRNA-mediated reduction
in Keap1 levels (Figure 2B) establish that the stability of the Neh2-
luc reporter directly depends on the expression level of Keap1.
In contrast to the previously utilized ARE-based promoter-
reporter constructs, the Neh2-luc reporter provides real-time
monitoring of Nrf2 stabilization and can be successfully used
for HTS purposes (see below) as well as in vivo bioluminescent
imaging.
Pilot HTS of Spectrum Library
The reporter cell line was stable for more than 1 year, providing
constant readings for all control Nrf2 activators. It has been
shown to be suitable for HTS purposes: the results of a pilot
screen of the Spectrum library using the Neh2-luc reporter cell
line with 10 mM TBHQ as a positive control are presented below.
TBHQ has been used in vivo for prophylaxis against ischemic
stroke (Shih et al., 2005). TBHQwas chosen among other canon-
ical activators tested because the concentration titration curve
had no peaks and showed a saturation plateau (Figure S1B),
and thus, was ideal for signal normalization. Induction of lucif-
erase activity is reported throughout as percentage of activation
by 10 mM TBHQ.
The screen revealed 224 hits exhibiting Neh2-luc reporter
activity equal or higher than 25% of TBHQ; among those, 100Ltd All rights reserved
Figure 3. Structural Formulas of HTS Hits
Activation effects are shown in percentage (%) for 16 mM of the representative hits. See also Figure S3 for other novel scaffolds found.
Chemistry & Biology
Reporter for Direct Monitoring of Nrf2 Activationshowed activation of at least 75% of that induced by TBHQ.
Thus, 5% of biologically active compounds and drugs presented
in the Spectrum library are at least 75% as potent as TBHQ in
activation of Nrf2. The prevalence of hits may reflect the impor-
tant role that Nrf2 plays in xenobiotic detoxification of a large
number of chemical entities.
As a further test of specificity of the identified Nrf2 activators,
we compared our 200 putative Nrf2 activators to almost 30 hits
from HTS of the same library found using a HIF1 ODD-luc
reporter as described in Smirnova et al. (2010). Upon hydroxyl-
ation at proline 564 in normoxia, the ODD-luciferase recruits
the E3 Ubiquitin Ligase, von Hippel-Lindau protein, targeting
the ODD-luciferase for proteasomal degradation (Smirnova
et al., 2010). The observation that the Nrf2 (Neh2-luc) or HIF1
(ODD-luc) screens of the identical 2000 compound library give
hits that do not overlap is the strongest evidence for specificChemistry & Biology 18,chemical control of the stability of both reporters. The findings
suggest that the rate-limiting step in reporter activation is
determined by Neh2 (of Nrf2) or ODD (of HIF1a), and not by pro-
teasomal degradation. In other words the reporters select unique
activators of Nrf2 and HIF1, respectively, and not common inhib-
itors of proteasomal degradation, as one may have criticized the
approach initially.
We found well-known drugs and hormones as potent activa-
tors of the Neh2-luc reporter, e.g., minocycline (Kuang et al.,
2009), sulindac, auranofin (Kataoka et al., 2001), teniposide,
and podophyllotoxin derivatives, all of which showed 200% acti-
vation over the canonical TBHQ-induced Neh2-luc response.
Purpurogallin carboxylates (Figure 3, Ic), prevalent components
of black tea, were extremely potent in activating the reporter up
to 500% of TBHQ levels. It is of interest to note that drinking
black tea three times a day was recently reported to delay752–765, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 755
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(Kandinov et al., 2009). We found representatives of all structural
classes (Figure 3) that were described previously as inducers of
the Nrf2-regulated gene nicotinamide quinone oxidoreductase 1
(NQO1) (Dinkova-Kostova et al., 2004). This fact provides addi-
tional evidence for reliability of the Neh2-luc reporter, which is
capable of identifying all hits reported previously using ARE-luc
reporter or those inducing Nrf2-dependent genes.
The hits included: phenolic antioxidants; diphenols (Figure 3, I);
aminophenols or their derivatives, e.g., acetaminophen exhibit-
ing more than 50% activation; phenylene diamines; substituted
coumarines, especially those containing adjacent hydroxy
groups (Figure 3, II); other cyclic lactones and enones; Michael
reaction acceptors such as fumaric, maleic, acrylic, crotonic,
ferulic, and caffeic acid derivatives, with bis-salicyl fumarate
(Figure 3, IIIa) being themost potent hit in this group (>300%acti-
vation); chalcones providing activation up to 400% (Figure 3,
IIIc); sappanones and sappanols; flavanones; and flavones (Fig-
ure 3, IV), such as 3,7,3040-tetrahydroxyflavone, fisetin, and
3,5,7,30,40-pentahydroxyflavone, quercetin (showing >300%
activation), and isoflavones such as koparin (>200%) and genis-
tein (>100%).
Structure-activity relationship studies for flavones indicate the
necessary presence of 3-hydroxy group because 30,4-dime-
thoxy-3-hydroxyflavone and kaempferol (3,5,7,40-tetrahydroxy-
flavone) are 2.5-fold less effective than quercetin and fisetin.
Luteolin (5,7,30,40-tetrahydroxyflavone) has an effect similar to
kaempferol, and thus, is much less active than fisetin and quer-
cetin, although they all have two adjacent hydroxy groups on
a freely rotating phenyl ring. Additionally, double Michael reac-
tion acceptors such as curcumins showing more than 200%
activation (Figure 3A, V), dithiolethiones, dimercaptans, and iso-
thiocyanates (Figure 3, VI) came up as hits. Sulforaphane (Fig-
ure 3, VIc) is the prototypic activator of Nrf2 (Figure S1A). Heavy
metals, such as cadmium and cisplatin, were also hits showing
modest activation of 30%–50%.
Of the 45 hits from the ARE-GFP screen of the same library
(Shaw et al., 2010), 37 of those were among our hits. The condi-
tions of HTS were very different, in particular the incubation time
(24 hr ARE-GFP versus 3 hr Neh2-luc), so some of the hits we
missed were likely to induce extremely delayed effects. The
lesser number of hits in ARE-GFP screen could reflect both pro-
longed incubation and lesser sensitivity of the assay: the cell
number per well was at least seven times higher and ebselen as
a positive control induced only a 3-fold increase in the reporter
signal (Shaw et al., 2010) compared to more than 10-fold activa-
tion by TBHQ in the case of Neh2-luc reporter (Figure 1B).Previously Unknown Classes of Nrf2 Activators
The previously unknown classes of hits included:
(1) All members of gedunin/khivorin family (18 compounds)
were among the hits (see Figure 3, group IX). The finding
of numerous gedunins as hits was unexpected.Moreover,
some of the tricyclic hits (Figure 3, group VII) resembled
the structure of gedunin very closely. The stereo effects
in play are obvious from comparison of tanshinone (Fig-
ure 3, VIIIa) and dihydrotanshinone (VIIIb), the major
components of danshen, one of the most important tradi-756 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 Elsevier Ltdtional Chinese medicines widespread in Asian countries:
both compounds have a clear quinone motif, but the
change from planar to 3D scaffold leads to a significant
increase in the reporter activation. Although one may
ascribe the effects of group VII and VIII compounds (Fig-
ure 3) exclusively to the presence of neighboring hydroxy
groups/quinone moiety, the activation by dihydroabieta-
mide (VIIc) cannot be explained by alkylation or redox-
cycling mechanism. The structure-activity relationship
within the gedunin/khivorin group (Figure 3, IX) clearly
points to the structural effects in play: the most remark-
able is the comparison between a- and b-dihydrogedu-
nols that differ only by the orientation of a hydroxy group
(activation effects are 40% and 220%, respectively).
(2) Planar Zn2+ chelators such as 8-hydroxyquinoline and
chloroacetoxyquinoline (60% activation). The presence
of Zn2+-atom in Keap1 was documented for the recombi-
nant protein produced in E. coli, and an estimate for Zn2+
binding constant was on the order of pM (Dinkova-
Kostova et al., 2005). We recently identified a number of
novel branched oxyquinolines as inhibitors of the HIF
prolyl hydroxylases (Smirnova et al., 2010). None of these
compounds (which are also zinc chelators with Ki below
200 nM) showed any Neh2-luciferase activation, pointing
to specific structural requirements for oxyquinoline zinc
chelators as Nrf2 activators. 3-Hydroxyflavone was found
as a modest Nrf2 activator and is known to bind zinc
better than 5-hydroxyflavone or 3040-dihydroxyflavone
(Lapouge et al., 2006).
(3) Adenosine, azathioprine, bromonitroindazole were
modest hits in our screen: they resemble the recently pub-
lished structures of Nrf2 inducers supposedly targeting
the IVR of Keap1 (Wu et al., 2010) (see Figure S3). In
that paper the authors performed virtual screening of
chemical databases for putative Nrf2 inducers showing
best scores for docking into the 3D model of the Keap1-
intervening domain with subsequent verification by
ARE-luciferase-based assay (Wu et al., 2010). They found
substituted purines with a freely rotating tetrahydrothio-
phene ring in the seventh position (BM10 and BM31 in
Figure S3), with lower potency than sulforaphane (Wu
et al., 2010). Of note, the tetrahydrothiophene ring is
extremely sensitive to oxidation, and it is not clear to
what extent themechanism of action of these compounds
can be ascribed to specific interaction with Keap1.Time Course of Reporter Activation as a Tool for Hit
Classification
As mentioned, the Neh2-luc reporter provides the possibility of
real-time monitoring for changes in the stability of Nrf2 in
the form of the luciferase-labeled Neh2 domain for the first
time. By following the kinetics of reporter activation, one may
expect to discriminate the mechanism of action of various Nrf2
activators, i.e., direct activators will exert immediate effects,
whereas those acting indirectly will show lag periods of different
durations.
The mechanism of Nrf2 activation has been postulated to
occur due to the chemical modification of key thiols in Keap1.All rights reserved
Figure 4. Confirmation of Neh2-luc Fusion Accumulation Using Anti-Luciferase Antibodies
Concentration dependence of luciferase signal for ‘‘switch’’-type hits (A and B) and confirmation of fusion protein accumulation by western blot (C). F, 3 hr
treatment with 5 mMfisetin; N, 5 mMNDGA; Q, 4 mMquercetin. The control cell linesWT-luc and HIF ODD-luc (Smirnova et al.,2010) did not accumulate luciferase
fusion under the same exposure conditions (see Figure S4).
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mechanism of action of redox-cycling compounds like ortho-
or para-dihydroxy-phenols is not known, although they are
supposed to undergo oxidation resulting in formation of potential
alkylating compounds.
Among well-known classes of hits, particularly those of cate-
chol type, with two adjacent hydroxy groups, e.g., fisetin, quer-
cetin, but not luteolin (class IV, Figure 3), and nordihydroguaia-
retic acid (NDGA, class I, Figure 3), demonstrated the best
parameters of activation, i.e., the lowest half-activation concen-
tration, the highest amplitude, and the lowest toxicity in the
concentration range, providing maximum activation of the
reporter. Moreover, in contrast to other hits of the screen, and
especially in comparison with the established Nrf2 activators
showing a gradual response on a concentration titration curve
(Figure S1B), NDGA and fisetin exhibit a very steep concentra-
tion response curve (Figures 4A and 4B).
We decided to undertake a separate study to use the kinetics of
reporter activation to compare the mechanism of action of our
best hits using the Neh2-luc reporter system. In addition to
providing a novel categorization of Nrf2 activators, our central
interest was to further characterize our best hits, which exhibited
a very steep concentration response over a very narrow range of
concentrations (Figure 4). An increase in Neh-2 luciferase activity
wasshown tocorrespond to theaccumulationof the fusionprotein
monitored by immunoblotting with selective anti-luciferase anti-
bodiesafter treatmentwithourmostpotent hits (Figure 4C).Under
basal conditions, no fusion protein was detectable, consistent
with a model in which Keap1 binding to the Neh2-luciferase trig-
gers its efficient proteasomal degradation (Figure 4C; Figure S4).
For the comparative studies we selected a number of hits, sus-
pected to work via different mechanisms: TBHQ, ortho-phenyl-
ene diamine (oPD), o-catechol, NDGA, quercetin, and fisetin as
representatives of redox-cycling compounds; sulforaphane,
and pyrithione as alkylating compounds; Cd2+, as a heavy metal
of unknown mechanism of action; and geldanamycin, specific
inhibitor of Hsp90 working via blockade of ATP-binding site
(Obermann et al., 1998), trichostatin A (TSA), a general inhibitor
of HDACs resulting in destabilization of Hsp90, and gedunin,
which is supposed to disrupt the association of Cdc37 and
Hsp90 (Brandt et al., 2008).
In accord with the time course of reporter activation (Figure 5),
we have classified hits into five groups: (1) immediate activationChemistry & Biology 18,but gradual stabilization over time, like sulforaphane, pyrithione,
TBHQ, quercetin, gedunin; (2) gradual stabilization with a barely
detectable (20 min) lag period (catechol); (3) gradual stabilization
with a short lag period of 40–50 min (oPD); (4) stabilization after
a prolonged lag period, 1–3 hr (Cd2+, TSA, geldanamycin); and
(5) activation via a switch or receptor, i.e., showing sharp conver-
sion fromalmost no effect to full activation over a narrow concen-
tration range (NDGA and fisetin—the best hits in the screen).
The similar behavior of TBHQ, sulforaphane, auranofin, pyri-
thione, and gedunin permits their classification into one group
of ‘‘alkylators.’’ Catechol is likely to undergo quick transforma-
tion and then also works as an ‘‘alkylator.’’ Apparently, oPD
and catechol behave differently: oPD has a clearly defined short
lag period, which may reflect the additional modification step of
the inducer, such as enzymatic oxidation with copper-depen-
dent enzymes (Wang et al., 2010); oPD is possibly the one
working through redox cycling.
The effect of Cd2+ is more than 1 hr delayed, so it either has
problems with getting into the cell or, more likely, has an indirect
effect on the system via inactivation of thiol-disulfide exchange
by inhibiting thioredoxin reductase/thioredoxin system. It is of
interest to note that increased concentrations of Cd2+ shorten
the lag period, whereas in the case of oPD, the lag period dura-
tion barely depends on the inducer concentration.
The activation effect observed with geldanamycin, a selective
Hsp90 inhibitor, was rather modest (2- to 3-fold in the range of
0.5–1.5 mM), with toxicity dominating at increased concentrations.
A characteristic feature of geldanamycin-inducedNeh2-luciferase
stabilization was an extremely prolonged (up to 3 hr) lag period,
similar to thatobserved for theglobalhistonedeacetylase inhibitor,
TSA (Figure 5). Of TSAs numerous effects, it is known to lead to
acetylation of Hsp90 and inhibition of its chaperone activity. The
long lag period of geldanamycin and TSA-induced activation
suggest Nrf2 activation as a downstream effect of Hsp90 inhibi-
tion.AlthoughgeduninhasalsobeendescribedasanHsp90 inhib-
itor, the absence of a lag period in gedunin-induced activation of
Neh2-luciferase (Figure 5) likely reflects direct disruption of
Neh2-Keap1 association. The titration behavior is similar to the
effect of alkylators of Cys151 in Keap1, except the magnitude of
the effect was much lower, and the activation plateau is clearly
observed at low, nonsaturated concentrations of gedunin.
As an independent approach to test the mechanism of action
of selected hits in comparison with the well-known controls, we752–765, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 757
Figure 5. Classification of HTS Best Hits Based on Kinetics of Reporter Activation
Switch-type activators (NDGA and fisetin); immediate alkylators (TBHQ, quercetin, sulforaphane, pyrithione); redox-cycling compounds undergoing prior
oxidation and showing lag period (catechol, o-phenylene diamine); heavy metals (cadmium) working via inhibition of thiol-disulfide exchange and corresponding
enzymes; Hsp90 inhibitors/destabilizers showing prolonged lag period (geldanamycin, TSA); and gedunin. Protein concentration 5.1 ± 0.2 mg per well. All values
are presented as mean ± SEM. Keap1-labeling experiments in the presence of selected hits show that only sulforaphane behaves as a potent alkyating agent
(see Figure S5).
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the presence of sulforaphane (positive control, alkylating agent),
TBHQ (positive control, redox-cycling compound), fisetin (hit),
quercetin (hit), gedunin (hit), geldanamycin (negative control,
working via Hsp90), and ciclopirox (negative control, not a hit).
All hits induce upregulation of Nrf2 target genes (Figure S5C).
As one may expect, only sulforaphane being a potent alkylating
agent shows a decent competition for the overexpressed
Keap1, whereas TBHQ, fisetin, quercetin, and gedunin (redox-
cycling compounds) demonstrate very modest competition (Fig-
ure S5B), indicative of either reversible modification of Keap1
cysteines or preference for particular cysteine residues in
Keap1. The labeling approach does not allow one to discriminate
between the mechanism of action of the hits, whereas the Neh2-
luc reporter assay clearly shows that all hits exert immediate
effects, although the time course patterns are different in shape
and magnitude.
Neuroprotective Effects of the Best Hits
To confirm that the best Neh2-luc activators identified from our
screen induce a neuroprotective response, we examined the758 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 Elsevierbiological effects of these activators on astrocyte-dependent
neuroprotection using an astrocyte-neuron coculture model of
oxidative stress. Specifically, Nrf2 activation in astrocytes
induces non-cell-autonomous neuroprotection via the transcrip-
tional regulation of genes involved generally in the antioxidant
response, including those involved in the biosynthesis, use,
and export of the major antioxidant glutathione (GSH) (Shih
et al., 2003). Glutamate or homocysteic acid (HCA, glutamate
analog) treatment of immature neurons leads to substantial
glutathione depletion in neurons and astrocytes and subsequent
oxidative stress-induced death of immature neurons; because
astrocytes possess ten times as much glutathione as neurons,
HCA-treated astrocytes remain viable (Haskew-Layton et al.,
2010). Thus, primary cultured astrocytes were pretreated with
NDGA, fisetin, or gedunin for 24 hr followed by the addition of
adjacent neurons in the presence of the GSH-depleting
compound, HCA. Pretreatment of the astrocytes with NDGA,
fisetin, or gedunin induced significant neuroprotection (Figures
6A–6C). As expected, all hits induced overexpression of Nrf2
target genes (Figures 6D and 6E) and a corresponding increase
in HO-1 protein levels (Figure 6F), themajor Nrf2-regulated gene.Ltd All rights reserved
Figure 6. Nrf2 Mediates the Astrocyte-Dependent Protective Effect of the Neh2-Luc Reporter Activators
(A–C) Cultured primary astrocytes were treated for approximately 24 hr with NDGA (A), fisetin (B), or gedunin (C). Immediately following complete wash off of the
treatments, primary immature neurons were plated in the presence or absence of HCA. Forty-eight hours later, neuronal viability was determined.
(D and E) Astrocytes were treated for 24 hr with 5 mMsulforaphane, 20 mM tBHQ, 10 mMNDGA, 24 mMgedunin, or 20 mMfisetin followed by RNA isolation. mRNA
for NADPH quinone oxidoreductase 1 (NQO1) (D) or heme oxygenase-1 (HO-1) (E) was quantified with real-time PCR.
(F) Astrocytes were treated for 24 hr with 5 mM sulforaphane, 20 mM fisetin, 24 mM gedunin, 5 mM NDGA (NDGA (5)), or 10 mM NDGA (NDGA (10)). Immunoblots
show HO-1 and b-actin, used as a loading control, immunoreactivity. The last lane is recombinant HO-1.
(G) Astrocytes were transfected with transfection reagent alone (Tsx-Ctl), a scrambled siRNA sequence (siScrml), or siRNA targeted against Nrf2 (siNrf2-1, siNrf2-
2, siNrf2-3) and treated with 5 mMsulforaphane (SF) for 24 hr (total siRNA treatment 48 hr). Immunoblots showHO-1 and b-actin immunoreactivity. The last lane is
recombinant HO-1 protein.
(H–J) Astrocytes were treated with siRNAs for 24 hr (Ctl, nontreated; Tsx, transfection reagent alone; siScr, scrambled siRNA, or siRNA targeted against Nrf2,
siN1, siN2, or siN3), followed by treatment with NDGA (H), fisetin (I), or gedunin (J) for 24 hr (total siRNA = 48 hr). Immediately following complete wash off of the
treatments, primary immature neurons were plated with or without HCA. Statistical significance was determined via one-way ANOVA, followed by post hoc
Dunnett’s test (A–C and H–J) or Student’s t test with Bonferroni correction (D and E). (A–C) *p < 0.05, comparisons are made within 5 mMHCA treatment groups
and are versus 5mMHCA alone. (D and E) **p < 0.01 all groups versus control. (H–J) *p < 0.05, versus Ctl NDGA plus HCA, Ctl fisetin plus HCA, or Ctl gedunin plus
HCA. See Figure S6 for control experiments.
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shows a boost in GSH, actually higher than classic Nrf2
activators, whereas fisetin does not show the same level ofChemistry & Biology 18,enhancement and is comparable to what we find with the clas-
sical Nrf2 activator TBHQ (Figure S6A). Fisetin is thought to
have multiple targets such as LOX, estrogen receptor, and752–765, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 759
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and off-target effects may negatively influence GSH levels. The
absence of a significant effect of fisetin on GSH levels does
not point to a Nrf2-independent mechanism because the Nrf2
target gene HO-1 in astrocytes has also been found to be neuro-
protective (Vargas et al., 2005).
To confirm that the astrocyte-dependent neuroprotective
effects were specific to the activation of Nrf2, astrocytes were
pretreated with siRNAs targeted against Nrf2. Three separate
Nrf2 siRNA sequences lead to reduced Nrf2 mRNA and protein
levels (Figures S6B and S6C) and reduced protein levels of
Nrf2-regulated HO-1 (Figure 6G). Sulforaphane, a canonical
Nrf2 activator, known to enhance astrocyte-dependent Nrf2-
mediated neuroprotection, was used as a positive control.
Consistent with prior results, Nrf2 knockdown with the Nrf2
siRNAs completely abrogated the sulforaphane-induced astro-
cyte-specific neuroprotection (Figure S6D). Additionally, the
protective effects of NDGA, fisetin, or gedunin were also abro-
gated with Nrf2 knockdown (Figures 6H–6J). We do not believe
that this reversal reflects the manifestation of toxic properties
of the compounds because Nrf2 knockdown in the absence of
oxidative stress did not lead to death in fisetin, NDGA, or gedu-
nin-treated cocultures.
As electrophiles, many of the canonical Nrf2 activators are
potential neurotoxins. Even a low level of electrophilic stress
would not be ideal for many neurological conditions where
oxidative stress is a contributor to disease pathology. Thus,
the identification of nonelectrophilic activators of Nrf2 is a high
priority. Importantly, in contrast to the neurotoxic effects of the
canonical Nrf2 activators such as TBHQ, the hits from our screen
(NDGA, fisetin, or gedunin) did not induce toxicity in isolated
neurons using a sensitive assay of neuronal vulnerability (Figures
S6E–S6I). It is worth noting that both NDGA and gedunin identi-
fied in this work as effective Nrf2 activators are key components
of herbal medicines used for centuries by Native Americans
(chaparral) and Indians (neem tree), respectively. These results
demonstrate that the Neh2-luc reporter system can be used to
identify potent and safe neuroprotective activators of the Nrf2
adaptive response.
DISCUSSION
Previous reporters of Nrf2 activation have utilized the ARE fused
to coding regions of firefly luciferase or human alkaline phospha-
tase in vitro or in vivo. The ARE-GFP construct was used to
screen the Spectrum library, and 45 hits were identified (Shaw
et al., 2010). The ARE-based reporters allow monitoring effects
of antioxidant response induced by Nrf2 stabilization only after
24 hr or longer. We have constructed a reporter system that
allows immediate monitoring of drug-induced Nrf2 stabilization
in the form of Neh2-luciferase fusion protein. The reporter
appears to be a physiological surrogate for Nrf2 based on
several observations: (1) Keap1 overexpression inhibits the
reporter activity, whereas Keap1 depletion stabilizes the reporter
(Figure 2); (2) canonical activators of Nrf2, which have been
shown to act by alkylating Keap1, lead to expected increases
in the Neh2-luciferase activity and protein (Figure S1B; Fig-
ure 4C); (3) representatives of all previously known classes of
Nrf2 activators as well as the majority of ARE-GFP screen hits760 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 Elsevier(Shaw et al., 2010) were identified in the Spectrum library using
the Neh2-luc reporter, further validating the assay (Figure 3);
and (4) activators of Nrf2 discovered in this screen protect
neurons from oxidative death via an Nrf2-dependent mechanism
in astrocytes (Figure 6).
The power of the Neh2-luc reporter allowed us to discriminate
between direct and indirect effects on reporter stabilization
induced by compounds tested in HTS, and, to our knowledge,
for the first time identify gedunin as a direct activator of Nrf2.
Recent studies suggest that gedunins are potent Hsp90 inhibi-
tors (Brandt et al., 2008). Celastrol, a quinone methide triterpe-
noid, is a known Hsp90 inhibitor (Zhang et al., 2008, 2009) as
well, and its derivative, dihydrocelastrol, was also found as
a modest hit in the screen. Based only on structural similarities
between gedunin and celastrol, one could speculate that gedu-
nin utilizes a similar mechanism of action via disrupting the inter-
action between Hsp90 and Cdc37, the cochaperone providing
a bridge between Hsp90 and client tyrosine kinases (Zhang
et al., 2008, 2009), which being detached from the Hsp90
complex undergo fast inactivation (usually within 40–45 min).
Of note, triterpenoids have been described as Nrf2 activators
using ARE-reporter mice and NQO1 induction levels (Yates
et al., 2007), and induce neuroprotection in a transgenic model
of Huntingtons disease (Stack et al., 2010). Withanolides, closer
analogs of gedunins, have been long known as inducers of
NQO1 (Dinkova-Kostova et al., 2004), and are also known to
disrupt Hsp90-Cdc37 interaction (Yu et al., 2010).
If gedunin works via the same mechanism as the aforemen-
tioned compounds, we should observe the delayed effect of
Hsp90 downregulation with all three compounds, e.g., gedunin,
geldanamycin, and TSA. However, the latter two show 3 hr lag
period in reporter activation, in contrast to the immediate effect
induced by gedunin (Figure 5). We may speculate that the direct
effect of gedunin originates from its competition with Nrf2 for
Keap1 based on the comparatively modest activation amplitude
and observed plateau in the time course of reporter activation
(Figure 5). This is in contrast to alkylating agents that drive the
system to the maximum activation linearly (see quercetin and
catechol in Figure 5). The plateau is a characteristic of re-equili-
bration of the system with reversible binding, or in other words,
gedunins may bind Keap1 reversibly. It is tempting to speculate
that gedunins compete with Nrf2 for Keap1 binding: the possi-
bility to design mild peptide-type inhibitors displacing Nrf2
from Keap1 like p62 does in vivo (Komatsu et al., 2010) has
been discussed in the paper with the resolved crystal structure
of Neh2-Keap1 DGR (Tong et al., 2007). This speculation is sup-
ported by computer modeling: gedunins fit perfectly into the
same Keap1-binding pocket as Nrf2 (Figure 7A), closely
following the bending of the 83FEGTE79 portion of the Nrf2
peptide (Figure 7B).
An important unanswered question is the mechanism of the
‘‘switch’’ effect demonstrated for our best hits, fisetin and
NDGA. The time course of NDGA and fisetin clearly shows that
they exert an immediate effect upon addition to the reporter
cell line; therefore, they act ‘‘as is’’ without prior chemical modi-
fication. Both NDGA and fisetin have adjacent hydroxy groups
on a freely rotating phenyl ring. This might suggest that these
adjacent hydroxy groups lead to reduction of a critical disulfide
bond. However, there is some doubt that fisetin and NDGALtd All rights reserved
Figure 7. Schematic Representation of
Different Mechanisms of Nrf2 Level Regula-
tion and Plausible Mechanism of Gedunin
Action
(A) Docking mode of gedunin in comparison with
the binding mode of Neh2 portion into Keap1.
(B) Overlap between Neh2 peptide and gedunin,
from perpendicular views.
(C) Hypothetic modes of Nrf2 level regulation (see
text for details).
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reducing agents capable of immediate reduction of dithionitro-
benzoate, a model disulfide, whereas NDGA is not. In addition,
luteolin, a flavone with potent reducing properties, with 3,4-dihy-
droxy-phenyl group present in fisetin, but hydroxyl group in posi-
tion 5, not 3, is a very poor Nrf2 activator. Moreover, catechol,
being a very potent reducing agent, does show a 20 min lag
period, which may reflect initial ‘‘priming,’’ most likely oxidation
that results in formation of its form capable of alkylating
Keap1. The fact that luteolin and catechol do not behave the
same way argues against this potential mechanism and points
to the special structural requirements for a ‘‘switch’’ mechanism
of Nrf2 activation.
A common and intriguing feature of our most promising hits,
fisetin and NDGA, is their steep concentration response, remi-
niscent of a ligand binding to a receptor. Of note, a common
feature of these hits is that they all have been reported to act
as inhibitors of protein tyrosine kinases, and NDGA in particular
was reported to target IGF1-R kinase. We also identified
genistein (100% reporter activation), which is well known for tar-Chemistry & Biology 18, 752–765, June 24, 2011geting this class of enzymes. Phosphory-
lation of Tyr141 in Keap1 is catalyzed by
an unknown protein tyrosine kinase and
is critical for Keap1 stability (Jain et al.,
2008). Protein tyrosine kinases are also
known to be stabilized by Hsp90, inhibi-
tors of which also came out in our screen
as hits.
The analysis of kinetics of individual
hits leads to the model scheme of Nrf2
regulation shown in Figure 7C. A key
role is played by Keap1 Cys151, 273,
288, for which modification with alkylat-
ing agents causes a dramatic change in
Keap1 conformation leading to Nrf2
stabilization. If Keap1 in vivo has a zinc
atom in the structure, we may hypothe-
size that the small planar Zn2+ chelators
identified in HTS may target and destabi-
lize the thiol pair in Keap1 as well. The
delayed effect of cadmium may reflect
the inhibition of thioredoxin reductase/
thioredoxin system, eventually compro-
mising the redox status of key cysteines
in Keap1. Regulation of Keap1 stability
via Hsp90-Cdc37-tyrosine kinase inter-
action is upstream of immediate activa-tion pathways. Hsp90 is a target for TSA and geldanamycin,
whereas NDGA and fisetin inhibit tyrosine kinase activity.
Gedunin, in addition to intercalation into the Hsp90-Cdc37 inter-
face, exerts an immediate effect on Nrf2 stabilization, possibly
by disrupting Nrf2-Keap1 interaction. With respect to fisetin
and NDGA, we also cannot rule out a possibility of targeting an
unknown site at the interface of Keap1 subunits (Figure 7C)
resulting in an immediate change in Keap1 conformation and
stabilization of Nrf2 because the scaffold of fisetin closely resem-
bles those of the hits generated by the virtual screen in Wu et al.
(2010) (Figure S3).
Canonical activators of Nrf2 such as TBHQ, isothiocyanates,
and the recently identified AL-I (Hur et al., 2010) appear to act
by modifying key cysteines in Keap1, the negative regulator of
Nrf2 stability. A major potential problem with electrophile activa-
tors of Nrf2 is their ability to induce toxicity, particularly in cells
vulnerable to redox stress such as neurons afflicted by ischemia
or neurodegeneration. The challenge is to find Nrf2 activators
that do not add to the overall oxidative load, and the reporter
provides a valuable resource for future developments towardª2011 Elsevier Ltd All rights reserved 761
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that are nontoxic to neurons over the range of concentrations
optimal for reporter activation (Figures S6E–S6I).
Activation of Nrf2 plays a key role in the antioxidant defense
of the central nervous system and has been shown to be
important for neuroprotection in several acute and chronic
neuropathological conditions such as stroke, intracerebral
hemorrhage, Parkinsons disease, Huntingtons disease, and
amyotrophic lateral sclerosis. Yet, Nrf2 activators such as
TBHQ, sulforaphane, or CDDO-triterpenoid are only now
making their way into the clinic (Shih et al., 2005; Chen et al.,
2009; Vargas et al., 2008). These findings highlight the biolog-
ical and clinical importance of a real-time assay for screening
and design of Nrf2 activators. The developed Neh2-luc reporter
is perfectly suited for HTS purposes, for studying the mecha-
nistic details of drug action, and by analogy with HIF ODD-luc
system (Safran et al., 2006), we are confident that the reporter
may be successfully used for in vivo imaging of Nrf2 activators
in animals.SIGNIFICANCE
Genetic antioxidant responses activated by electrophiles
are currently monitored via the use of reporters such as
firefly luciferase, human alkaline phosphatase, or GFP
driven by a canonical antioxidant response element (ARE).
Activators of this pathway lead to the stabilization of
Nrf2 and induction of dozens of genes that have been shown
to prevent cancer, neurodegeneration, proinflammatory
states, and combat atherosclerosis. There is a lack of
compelling bioassay to ensure real-time monitoring of anti-
oxidant response.Wepresent a reporter basedonaprinciple
different than the widely used ARE-luciferase. The devel-
oped reporter constitutively expresses the Neh2 domain of
Nrf2 fused to firefly luciferase. The steady-state concentra-
tion of Nrf2 (as represented by Neh2 luciferase) established
in cells can be manipulated by the addition of compounds
affecting the individual steps controlling the Nrf2 stability.
The Neh2-luc reporter allows monitoring the antioxidant
response in real time, right after drug administration,
and is suitable both for high throughput screening and
elucidation of the mechanism of drug action. The power of
the Neh2-luc reporter is illustrated by its application for
screening of the Spectrum library followed by real-time
monitoring of action of selected hits: in addition to the iden-
tification of Nrf2 activators, we make an insight into the
mechanistic details of their action and offer a strategy
to discriminate between the action of direct activators
such as alkylating agents and those requiring additional
transformation steps such as prior oxidation (catechols
and diamines) or manipulation of upstream regulatory
pathways (via Hsp90 inhibition). Gedunins and their struc-
tural analogs were identified as a novel pharmacological
class of Nrf2 activators. We also provide biological evidence
for Nrf2-dependent neuroprotective roles played by identi-
fied Nrf2 activators—fisetin, nordihydroguaiaretic acid, and
gedunin—in an established model of oxidative stress in
neuron-astrocyte coculture.762 Chemistry & Biology 18, 752–765, June 24, 2011 ª2011 ElsevierEXPERIMENTAL PROCEDURES
Materials
Cell lines, primary neuronal and astrocyte cultures, see Supplemental Experi-
mental Procedures.
Reporter Plasmid Construction
DNA fragment encoding 1–97 aa residues of Neh2 domain of NRF2 was the
product of PCR with a cDNA template obtained from total RNA isolated from
SH-SY5Y cells by using NucleoSpin RNAII kit (MACHEREY-NAGEL) and
used for cDNA synthesis by SuperScript III First-Strand Synthesis System
for RT-PCR (Invitrogen). Neh2 fragment flanked with HindIII and NarI sites
was amplified using Advantage 2 Polymerase Mix (Clontech) and the following
primers: HINDNRF: CCCAAGCTTGGATCCGAATTCGCCACCATGATGGACT
TGGAGCTGCCGCCGCC; and NARNRF: TAGAATGGCGCCGGGCCTTTCTT
TATGTTTTTGGCGTCTTCACTGGTTTCTGA. Then it was inserted into HIindIII
and NarI sites of pGL3-control (Promega) to obtain pGL3NEH2LUC. The
HindIII-XbaI DNA fragment of pGL3NEH2LUC-encoding fusion protein
Neh2-luciferase was cloned into corresponding sites of pcDNA3 (Invitrogen) to
obtain pcDNA3-Neh2LUC10. The HIF ODDLUC-encoding plasmid pcDNA3-
ODDLUC8 was constructed as described previously (Smirnova et al., 2010).
pcDNA3-LUC3 encoding plain luciferase was made by insertion of HindIII-
XbaI fragment of pGL3-control into HindIII-XbaI sites of pcDNA3 . The ARE-
luciferase construct contained an ARE promoter consensus sequence as
derived from the human NADPH quinone oxidoreductase gene (50-CTCAGCC
TTCCAAATCGCAGTCACAGTGACTCAGCAGAATC-30), upstream of a lucif-
erase reporter (Moehlenkamp and Johnson, 1999).
Methods
HTS Optimization and SAR Analysis
The assay was optimized for HTS format to provide Z values above 0.7. SH-
SY5Y-Neh2-luc cells were plated into 384-well, white, flat-bottom plates at
7000 cell/well in 30 ml serum and incubated overnight at 37C, 5% CO2. The
next day, compounds were added to two final concentrations of 16 and
32 mM, plates were incubated for 3 hr at 37C, and luciferase activity was
measured using SteadyGlo reagent (Promega). Each plate had two internal
standards, TBHQ (100%) and DMSO (0%). The reporter activation (%) was
calculated as a ratio (LLDMSO)/(LTBHQLDMSO). Hits were defined as those
greater than 25%. HTS of 2000 compounds was performed at Rockefeller
University HTS Resource Center. A total of 224 hits from the initial screen
have been tested in duplicate, and 210 were confirmed. Classification into
structural clusters has been done manually (see also Table S1). The line
expressing WT luciferase under the same promoter was used to evaluate the
effect of all compounds from the Spectrum library on luciferase activity. None
was found to inhibit/enhance the luciferase activity under the experimental
conditions, whereas 46 compounds were found to be toxic at 3 hr incubation
and were excluded from consideration. The previously described HIF1 ODD-
luc reporter line (Smirnova et al., 2010) was used as a control for specificity.
Extended SAR Analysis
Selected hits were tested in 96 format white, flat-bottom plates with varied
concentrations of an inhibitor (0.05–25 mM). Cells were plated at the density
of 25,000 cells per well using a WellMate multichannel dispenser from Matrix
(Thermo Fisher Scientific) and grown overnight on DMEM/F12 plus GlutaMAX
(100 ml per well). Then the inhibitor was added, and the plates were incubated
for a fixed time interval; themediumwas removed, cells were lysed in 20 ml (out
of which 4 ml was taken for protein measurement), then BrightGlo reagent
(Promega) was added to the wells and luciferase activity measured on a lumin-
ometer Lmax11384 (Molecular Devices). The reporter activation was normal-
ized to the background luminescence divided by protein concentration.
Kinetics of reporter activation were measured by adding varied fixed concen-
trations of an inhibitor at different time points followed by simultaneous cell
lysis, protein determination, and luciferase activity measurement in the whole
96-well plate; this assay format minimizes experimental error originating from
the well-known instability of luciferase reagent.
Computer Modeling
Docking experimentswere performedusing theCDOCKERalgorithm, followed
by force fieldminimization and binding energy calculations using themolecular
mechanics algorithm CHARMm (as implemented in Discovery Studio 2.5,
Accelrys, San Diego, CA, USA). The crystal structure of human Keap1 kelchLtd All rights reserved
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hydrogen atoms added was used as the starting template structure.
siRNA Keap1 Knockdown
siRNA against human Keap1 and control nonspecific siRNA were purchased
from Thermo Scientific Dharmacon. Neroblastoma SH-SY5Y cells carrying
pcDNA3-Neh2LUC10 or pcDNA3-LUC3 were plated at 3 3 105 cells per
well in 6-well plate. Next-day cells were transfected with ON-TARGETplus
SMARTpool siRNA Keap1 and ON-TARGETplus Non-Targeting Pool using
Lipofectamine 2000 (Invitrogen) according protocol. Transfected cells were
probed in luciferase assays and quantitative real-time PCR analysis 24, 48,
and 72 hr after transfection with siRNA.
Real-Time Polymerase Chain Reaction
Total RNA was isolated from SH-SY5Y cells by using NucleoSpin RNAII kit
(MACHEREY-NAGEL) and used for cDNA synthesis by SuperScript III First-
Strand Synthesis System for RT-PCR (Invitrogen). Quantitative real-time
PCR analyses of human KEAP1, GCLC, GCLM, HO-1, and NQO1 were per-
formed by using the corresponding primers and probe set from Applied
Biosystems on the ABI 7500 Fast Real-Time PCR TaqMan system (Applied
Biosystems). GAPDH was used for normalization.
Western Blotting
Cell cultures were rinsed in PBS, then lysed and scraped in RIPA buffer
(Boston BioProducts) with 1% Protease Inhibitor Cocktail (Sigma). Lysates
were vortexed, incubated on ice for 15 min, sonicated, and stored at 80C.
Protein concentration was determined using BCA Protein Assay Kit (Pierce/
Thermo Scientific, Rockford, IL, USA). Samples were diluted in water to
equalize protein concentration, mixed with Laemmli SDS sample buffer
(reducing, 43), boiled at 100C for 5 min, cooled on ice, and centrifuged at
13,000 3 g for 1 min immediately before gel loading. Samples were resolved
by SDS-PAGE using 10% gels run at 120 V for 2 hr and transferred onto
nitrocellulose membranes at 100 V for 1 hr. Quantitative western blots were
performed according to the Western Blot Analysis protocol supplied by LI-
COR Biosciences (Doc# 988-09288). Primary antibodies used were mouse
monoclonal antibody for luciferase sc-74548 diluted 1:1,000 (Santa Cruz
Biotechnology), rabbit polyclonal antibody for b-actin A2066 diluted 1:10,000
(Sigma), and a rabbit polyclonal antibody for heme oxygenase-1 (Stressgen;
1:1,000). Secondary antibodies used were goat anti-Rabbit IR dye 680 and
goat anti-mouse IRDye 800CW (LI-COR Biosciences).
Keap1 Labeling by Sulfoxythiocarbate-Alkyne in Cells
Keap1-labeling experiments were performed as described previously
(Ahn et al., 2010) with following modifications. HEK293 cells transiently ex-
pressing FLAG-Keap1 were incubated with 200 mM competing compounds
(sulforaphane, fisetin, quercetin, gedunin, TBHQ, ciclopirox, geldanamycin)
in serum-free DMEM for 1 hr. After washing with PBS, cells were further incu-
bated with 10 mM STCA for 30 min at 37C. FLAG-Keap1 was immunoprecip-
itated from cell lysates, subjected to click reaction with biotin azide on beads,
and eluted with SDS-loading buffer. Eluted samples were immunoblotted with
Streptavidin-HRP (Pierce) and anti-FLAG antibodies (Sigma).
Adenoviral Transduction
Adenoviral vectors containing cDNA for Nrf2 or Keap1 were obtained from the
laboratory of Timothy H. Murphy. Nrf2 was driven by a CMV promoter,
and a separate CMV promoter also drove the expression of GFP. Keap1
was driven by a CMV promoter and contained a FLAG tag. Cells were treated
with the adenoviral plasmids at a multiplicity of infection (MOI) equal to 25
for 4 hr in serum-free Opti-MEM media and used 24–48 hr following
transduction.
Neuronal Viability
Neuronal viability was quantified using a modified protocol (Carrier et al.,
2006). Astrocyte-neuron cocultures were 4% paraformaldehyde fixed for
0.5 hr at 37C, then incubated with antibodies against the neuronal-specific
marker microtubule-associated protein 2 (polyclonal anti-MAP2, 1:500, in
4% normal goat serum and 0.3% Triton-X 100) overnight at 4C. Then the cells
were incubated with rabbit secondary antibodies conjugated with horseradish
peroxidase (anti-rabbit-HRP, 1:1250, in 4% normal goat serum and 0.3%
Triton-X 100) for 0.5 hr at RT. The fixed cells were incubated with a reaction
buffer containing 150 mM Amplex Red and 800 mM H2O2 made up in basal
media (135 mM NaCl, 3.8 mM KCl, 1.2 mM MgSO4, 1.3 CaCl2, 1.2 mM
KH2PO4, 10 mM D-glucose, 10 mM HEPES [pH 7.4]) for approximately
0.5 hr at RT; the formation of resorufin was measured on a SpectraMax PlusChemistry & Biology 18,384 (Molecular Devices) at 560 nm at RT. To account for the nonspecific
binding of MAP2 to astrocytes, values determined for astrocytes alone were
subtracted from coculture values.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:10.
1016/j.chembiol.2011.03.013.
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